Table 3.
Research on early GC diagnosis biomarkers from omics data
| Omics level | Sample category | Biomarkers | Performance index odds ratio (95% confidence interval) | Refs |
|---|---|---|---|---|
| Cellular | Tissue samples | KLK10 | N/A | 33 |
| Molecular | Tissue samples | Somatic TP53 mutation | Six positive among 9 EGC-coexisting HG-IEN lesions | 72 |
| Molecular | Tissue samples | Somatic TP53 mutation | N/A | 73 |
| Molecular | Tissue samples | CDH17 | N/A | 74 |
| Molecular | Tissue samples | miR-30 miR-194 |
N/A | 77 |
| Molecular | Tissue samples | miR-143-3p | N/A | 78 |
| Molecular | Tissue samples |
APOA1BP
PGC HPX DDT |
IM/LGIN vs. SG/CAG APOA1BP: 0.71(0.45–1.11) PGC: 0.33(0.19–0.57) HPX: 1.45(0.69–3.05) DDT: 0.71(0.45–1.11) |
79 |
| Molecular | Plasma samples | Sn-2 LysoPC(20:3) Sn-1 LysoPC(18:3) α-Linolenic acid Linoleic acid Palmitic acid Arachidonic acid |
IM/LGIN vs. SG/CAG Sn-2 LysoPC(20:3): 1.31 (0.93–1.87) Sn-1 LysoPC(18:3): 1.26 (0.90–1.77) α-Linolenic acid: 1.09 (0.78–1.53) Linoleic acid: 1.12 (0.80–1.56) Palmitic acid: 1.23 (0.89–1.71) Arachidonic acid: 1.35 (0.98–1.88) |
80 |
| Molecular | Plasma samples | PC38:6(20:4) PC38:5(20:4) PA32:1 LPI18:0 LPI20:4 FFA20:4 FFA18:3 FFA18:0 LysoPC18:3 LysoPC20:4 PC34:3 |
GC vs. IM/LGIN PC38:6(20:4): 0.61 PC38:5(20:4): 0.74 PA32:1: 0.50 LPI18:0: 0.58 LPI20:4: 0.13 FFA20:4: 0.50 FFA18:3: 0.50 FFA18:0: 0.58 LysoPC18:3: 0.31 LysoPC20:4: 0.17 PC34:3: 0.60 |
81 |
| Molecular | Tongue-coating samples | Campylobacter concisus | N/A | 20 |
| Molecular | Tissue samples | FBXW7 mutation | 4.7% in gastric biopsies | 50 |
| Molecular | Tissue samples | RNF43 mutation | 35.2% in EGC-adenomas | 82 |